Denali therapeutics announces successful meeting with the fda and plans to file for accelerated approval of tividenofusp alfa (dnl310) for the treatment of mps ii (hunter syndrome)

South san francisco, calif., sept. 03, 2024 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli) today announced the outcome of a recent successful meeting with the center for drug evaluation and research (cder) division of the u.s. food and drug administration (fda) providing a path to filing a biologics license application (bla) for accelerated approval and subsequent conversion to full approval for tividenofusp alfa (dnl310) for the treatment of mps ii (hunter syndrome). agreement was reached that cerebrospinal fluid heparan sulfate (csf hs) is reasonably likely to predict clinical benefit and can be used as a surrogate endpoint to support accelerated approval for tividenofusp alfa in mps ii. based on discussions with cder, denali will include preclinical and clinical data on biomarkers (csf hs and neurofilament light (nfl)) and safety in the bla for tividenofusp alfa as a treatment of mps ii and intends to submit the bla under the accelerated approval pathway in early 2025.
DNLI Ratings Summary
DNLI Quant Ranking